Mirador Capital Partners LP Increases Stock Holdings in Pfizer Inc. (NYSE:PFE)

Mirador Capital Partners LP boosted its position in Pfizer Inc. (NYSE:PFEFree Report) by 6.6% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 81,647 shares of the biopharmaceutical company’s stock after purchasing an additional 5,084 shares during the quarter. Mirador Capital Partners LP’s holdings in Pfizer were worth $2,351,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. Worth Asset Management LLC acquired a new position in Pfizer in the 1st quarter valued at $29,000. Briaud Financial Planning Inc acquired a new position in Pfizer in the 3rd quarter valued at $30,000. GoalVest Advisory LLC increased its stake in shares of Pfizer by 304.9% in the 4th quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock worth $31,000 after acquiring an additional 811 shares during the last quarter. Mizuho Securities Co. Ltd. acquired a new stake in shares of Pfizer in the 3rd quarter worth $34,000. Finally, VisionPoint Advisory Group LLC increased its stake in shares of Pfizer by 52,350.0% in the 3rd quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock worth $35,000 after acquiring an additional 1,047 shares during the last quarter. 68.36% of the stock is owned by institutional investors and hedge funds.

Pfizer Stock Down 0.1 %

Shares of PFE traded down $0.03 during midday trading on Friday, hitting $27.75. The company had a trading volume of 40,466,657 shares, compared to its average volume of 46,954,156. The company’s 50-day simple moving average is $27.44 and its 200-day simple moving average is $29.41. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.69 and a current ratio of 0.91. The firm has a market capitalization of $157.14 billion, a P/E ratio of 77.08, a P/E/G ratio of 1.24 and a beta of 0.61. Pfizer Inc. has a 1 year low of $25.61 and a 1 year high of $42.22.

Pfizer (NYSE:PFEGet Free Report) last announced its quarterly earnings data on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.19) by $0.29. The business had revenue of $14.25 billion during the quarter, compared to analysts’ expectations of $14.37 billion. Pfizer had a return on equity of 10.88% and a net margin of 3.62%. The business’s quarterly revenue was down 41.3% compared to the same quarter last year. During the same quarter last year, the business posted $1.14 EPS. As a group, sell-side analysts expect that Pfizer Inc. will post 2.22 EPS for the current year.

Wall Street Analyst Weigh In

PFE has been the subject of a number of recent research reports. Barclays cut their target price on Pfizer from $34.00 to $28.00 and set an “equal weight” rating for the company in a research note on Thursday, December 14th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $45.00 target price on shares of Pfizer in a research note on Friday, March 1st. Argus downgraded Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. Guggenheim began coverage on Pfizer in a research note on Friday, February 23rd. They issued a “buy” rating and a $36.00 target price for the company. Finally, TD Cowen downgraded Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price objective for the company. in a research report on Thursday, January 4th. Twelve equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $36.88.

Check Out Our Latest Research Report on PFE

About Pfizer

(Free Report)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Read More

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFEFree Report).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.